Vicryl Rapide Versus Nonabsorbable Suture
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 12, 2019
Trial Information
Current as of September 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of stitches used for closing wounds caused by accidents, specifically looking at Vicryl Rapide versus nonabsorbable sutures. The goal is to find out if Vicryl Rapide, which dissolves over time, is just as effective as the traditional nonabsorbable stitches in terms of how well the wound looks three months after it has been stitched. The study will take place in the emergency department at Community Regional Medical Center.
To be eligible for the trial, participants must be at least 18 years old and have a single laceration on their trunk or extremities that is longer than 2 centimeters and needs to be closed with simple stitches. People with certain conditions, like high-risk infections or complicated wounds, won't be able to participate. If you join the study, you can expect to receive either type of suture for your wound and will be asked to return for a follow-up appointment in three months to assess how well the wound has healed. This trial is currently recruiting participants, and both men and women can take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient 18-years or older
- • single laceration on trunk or extremity requiring suture closure
- • laceration length \> 2-cm
- • wound to be closed with simple interrupted sutures
- Exclusion Criteria:
- • High infection potential
- * Must have one of the following:
- • puncture wound
- • -highly contaminated
- • devitalized tissue requiring sharp debridement
- • -bite wounds
- • -\> 24-hours-old
- • Low likelihood of good cosmesis
- * Must have one of the following:
- • -dehisced wound from previous wound closure
- • -wound
- • -crush wound
- • -soft tissue deficit limiting complete apposition of wound edges
- • -significant overlying macerated/abraded tissue
- • Underlying tendon or cartilage involvement
- • -Wound greater than 10 cm in length
- • Significant wound healing problems
- * Must have one of the following:
- • keloid formers
- • chronic steroid use
- • other: ______________________ -Inability to give written consent
- * Must have one of the following:
- • non-English or non-Spanish speaker
- • altered mental status
- • incarcerated patient
- • No telephone number or unlikely to return for 3-month follow-up
- * Must have one of the following:
- • homeless
- • psychiatric patient,
- • nursing home patient,
- • other: ______________________
- • More than one laceration needing suture repair on trunk or extremity (i.e. appropriate to proceed if second laceration is to face/neck)
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fresno, California, United States
Fresno, California, United States
Patients applied
Trial Officials
Brian Chinnock, MD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials